Alzamend Neuro, Inc.
ALZNHealthcareNASDAQBiotechnology · Last scanned Oct 24, 2026
Scan Results
Daily timeframeAlzamend Neuro, Inc., a clinical-stage biopharmaceutical company, focuses on developing various products for the treatment of neurodegenerative and psychiatric disorders. The company carries a $5.5M market cap, placing it firmly in the micro-cap category. The company's pipeline includes AL001, which delivers a therapeutic combination of lithium, proline, and salicylate for the treatment of Alzheimer's, bi-polar disorder, post-traumatic stress disorder, major depressive disorder, other neurodegenerative diseases, and psychiatric disorders; and ALZN002, which uses a method using a mutant-peptide sensitized cell as a cell-based therapeutic vaccine to restore the ability of a patient's immunological system to combat Alzheimer's disease.
Market Cap
$5.5M
Beta
0.27
P/E (TTM)
—
P/E (Fwd)
-1.30
EPS (TTM)
$-2.30
EPS (Fwd)
$-0.87
ROE
-163.2%
ROA
-76.4%
Cash
$7.6M
Total Debt
$0
Free CF
-$3.4M
52W Change
-54.6%
Annual Financials
Cash vs Debt
Where ALZN stands vs its 150-day and 200-day moving averages
As of the October 20, 2026 close, ALZN finished 0.75% below its 150-day moving average ($1.34) and 12.50% below its 200-day moving average ($1.52). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is ALZN overbought or oversold?
At the October 20, 2026 close, ALZN's RSI(14) was 21.5, in oversold territory (below 30). The MACD histogram was negative, so short-term momentum leaned bearish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
Alzamend Neuro, Inc. reports $7.6M in cash and $0 in total debt. The company is burning cash, with free cash flow at -$3.4M. This typically occurs when a company is investing aggressively in growth, but sustained cash burn can strain the balance sheet. Return on equity stands at -163.2%, which is negative for the sector. ROE measures how effectively a company uses shareholder capital to generate profits.
With a beta below 0.7, Alzamend Neuro, Inc. typically sees smaller price swings than the overall market, offering a degree of stability during turbulent periods. The company is burning cash at the operating level, which is not unusual for growth-phase companies but adds risk if it persists. No single metric tells the full story. Reviewing ALZN's risk profile alongside its fundamentals and technical indicators provides a more complete picture.